MethMax
Maximization of treatment effect
Project managers
ABOUT THE PROJECT
MethMax is a clinical study to investigate whether giving methotrexate subcutaneously, as a syringe under the skin, gives a better effect than giving tablets. Methotrexate is the most common arthritis medication, and most patients with arthritis start methotrexate shortly after diagnosis. The study is part of the SQUEEZE project, which is a European collaboration that has received over NOK 100 million for arthritis research from Horizon Europe, the EU's research programme.
WHO CAN JOIN?
Patients over 18 years of age diagnosed with rheumatoid arthritis (arthritis) who are treated with methotrexate. Recruitment of participants has not yet begun.
WHAT DOES THE STUDY INCLUDE?
More information about the SQUEEZE project, of which MethMax is a part:
https://www.remedy-senter.no/project/squeeze
https://squeeze-project.eu/
This project has received funding from the European Union's Horizon Europe research and innovation program under grant agreement no. 101095052. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.